longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

VG Health

VHT

----
Start trading
OverviewOverviewNewsNewsPostsPostsWikiWikiRatingsRatingsCompositionCompositionDividendsDividends
LongbridgeAI
  • Neuphoria Therapeutics Inc. FY 2026: Revenue $1.17M, Net loss $13.59M — 10-K Summary

    TradingView·12 hours ago
    NEUP-0.40%MRK-0.19%
  • Security National Bank of Sioux City Iowa IA Purchases 1,560 Shares of Thermo Fisher Scientific Inc. $TMO

    Market Beat·10 hours ago
    TMO-1.04%
  • Weekly Recap | Merck +2.04%, most brokers rate it buy

    Weekly Review·2 hours ago
    MRK-0.19%
  • JNJ Announces CHMP's Recommendation For Approval Of TECVAYLI

    rttnews·20 hours ago
    JNJ-0.09%
  • Health Canada authorizes Pfizer-BioNTech XFG-adapted COVID-19 vaccine

    PUBT·1 day ago, 05:30 PM
    - Health Canada authorized the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for individuals aged 6 months and older for the 2026 - 2027 season. - The updated mRNA vaccine specifically targets the Omicron XFG lineage. - Doses are scheduled to roll out across Canada through multiple distribution channels in the coming days and weeks.
    BNTX-2.64%PFE+0.07%
  • Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) | MRK Stock News

    StockTitan·1 day ago, 02:55 AM
    MRK-0.19%
  • GENSCRIPT BIO Spikes 16%+ after Reaching Co-op with Eli Lilly's TuneLab

    AASTOCKS News·2 days ago, 04:00 AM
    01548+5.70%LLY+0.04%
  • Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year’

    Market Beat·1 day ago, 10:02 AM
    TMO-1.04%
  • AbbVie says real-world studies show Vraylar improves symptoms in MDD, bipolar I depression

    PUBT·20 hours ago
    ABBV-0.02%
  • J&J Slips as Caplyta Clears a Quality-of-Life Test

    GuruFocus·2 days ago, 07:29 PM
    JNJ-0.09%ITCI0.00%
  • AbbVie (ABBV) Could Be 4% Undervalued After Phase 3 Trial Wins

    Simplywall·1 day ago, 02:03 PM
    ABBV-0.02%
  • TileDB Rebrands as Tile.ai, Names New CEO and Secures Strategic Investment

    prnewswire·2 days ago, 02:02 PM
    AMGN+1.55%
  • Abbott Laboratories declares $0.63 dividend

    businessinsider·1 day ago, 05:31 PM
    ABT+0.37%
  • Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

    MorningStar·1 day ago, 10:52 PM
    GILD-0.52%GIS
  • Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff

    Market Beat·1 day ago, 07:02 PM
    JNJ-0.09%